Ardelyx to Report Third Quarter 2026 Financial Results on November 3, 2026
Key Highlights
- ➤Ardelyx will report third-quarter 2026 financial results November 3, 2026
- ➤Management will provide a third-quarter business update during the webcast
- ➤Ardelyx has two U.S.-approved commercial products, IBSRELA and XPHOZAH
- ➤Pipeline includes Phase 3 IBSRELA development and next-generation NHE3 inhibitor RDX10531
WALTHAM, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx Inc. (Nasdaq: ARDX), (“Ardelyx” or the “Company”) a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced that management will host a webcast and conference call on Tuesday, November 3, 2026, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the third quarter of 2026.
Webcast Information A live webcast of the conference call and accompanying slides will be available in the “Events and Presentations” section under “News and Events” within the Investors section of the Company’s website at www.ardelyx.com.
Get started
Create a free account to read the full story.